Fig. 2: Selected kinase inhibitors induce neurite-like process outgrowth in GBM cells, GSCs and astrocytes.
From: PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling
A Average length of neurite-like process per cell was determined for normal AS and GBM cell lines U87, U138 and LN229 treated for 24 h with 1 μM of the kinase inhibitor hits from the screening (LY2835219 (CDK4/6), pelitinib (EGFR), CP-673451 (PDGF-Rα/β) and pacritinib (JAK2/FLT3)). Representative images shown, red arrows indicating neurite-like processes. Images taken at 20x mag, Scale bar = 100 μm. B Average length of neurite-like process per cell was determined for patient-derived GSCs G166, GS090 and G179 treated for 48 h with 1 μM of the kinase inhibitor hits from the screening (LY2835219 (CDK4/6), pelitinib (EGFR), CP-673451 (PDGF-Rα/β) and pacritinib (JAK2/FLT3)). Representative images shown, red arrows indicating neurite-like processes. Images taken at 20x mag, Scale bar = 100 μM. C, D qRT-PCR performed on U87 GBM cells (C) and G179 GSCs (D) treated with 1 μM CP-673451 for 96 and 48 h, respectively, measuring the relative mRNA expression levels (fold change normalised to GAPDH compared to control levels) of cell specific markers astrocytic (GFAP, ALDH1L1), neural (β3-tubulin, NEFL) stem cell (Nestin, PROM-1) oligodendrocyte (Oligo) (OLIG-2, CSPG4) and mesenchymal (VEGFA, CD44). Average of a minimum three biological repeats t-test *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.
